For Immediate Release: November 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, […]

[11-22-2024] The Food and Drug Administration is advising consumers not to purchase or use Force Forever, a product promoted and sold for joint pain on various […]

[11-22-2024] The Food and Drug Administration is advising consumers not to purchase or use THERMO SHOCK, a product promoted and sold for weight loss on various […]

Over 7,000 rare diseases affect more than 30 million people in the United States. Many rare conditions are life-threatening and most do not have treatments. Drug, […]

The Reagan-Udall Foundation for the Food and Drug Administration (the Foundation) is an independent 501(c)(3) organization created by Congress “to advance the mission of the FDA […]

On November 20, 2024, the Food and Drug Administration granted accelerated approval to zanidatamab-hrii (Ziihera, Jazz Pharmaceuticals, Inc.), a bispecific HER2-directed antibody, for previously treated, unresectable […]

Image By: Justin D. Green, MBA, MDiv., Assistant Commissioner, FDA Office of Criminal Investigations A few significant ways the U.S. Food and Drug Administration protects public […]

Summary Company Announcement Date: November 19, 2024 FDA Publish Date: November 20, 2024 Product Type: Drugs Reason for Announcement: Recall Reason Description The product contains undeclared […]

Summary Company Announcement Date: July 16, 2024 FDA Publish Date: July 17, 2024 Product Type: Drugs Reason for Announcement: Recall Reason Description Mislabeled with the incorrect […]